Probiotics and irritable bowel syndrome

References

• Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006; 130: 1480–91. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006; 130: 1377–90. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Talley NJ. Irritable bowel syndrome. Intern Med J. 2006; 36: 724–8. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Clarke G, Cryan JF, Dinan TG, Quigley EM. Review article: probiotics for the treatment of irritable bowel syndrome – focus on lactic acid bacteria. Aliment Pharmacol Ther. 2012; 35: 403–13. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Lee BJ, Bak YT. Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil. 2011; 17: 252–66. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Pineiro M, Stanton C. Probiotic bacteria: legislative framework – requirements to evidence basis. J Nutr. 2007; 137: 850S–3S.
   PubMed Web of Science ®Google Scholar
• O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005; 128: 541–51. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101: 1581–90.
   PubMed Web of Science ®Google Scholar
• Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life – a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011; 33: 1123–32. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier CH, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther. 2007; 26: 475–86. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Nobaek S, Johansson ML, Molin G, Ahrné S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol. 2000; 95: 1231–8. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis. 2000; 32: 294–301. 10.3402/mehd.v23i0.18573.
   PubMedGoogle Scholar
• Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2001; 13: 1143–7. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Bausserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr. 2005; 147: 197–201. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Gawronska A, Dziechciarz P, Horvath A, Szajewska H. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther. 2007; 25: 177–84. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Sinn DH, Song JH, Kim HJ, Lee JH, Son HJ, Chang DK, et al. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci. 2008; 53: 2714–8. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Francavilla R, Miniello V, Magistà AM, De Canio A, Bucci N, Gagliardi F, et al. A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics. 2010; 126: e1445–52. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci. 2002; 47: 2615–20. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Newcomer AD, Park HS, O'Brien PC, McGill DB. Response of patients with irritable bowel syndrome and lactase deficiency using unfermented acidophilus milk. Am J Clin Nutr. 1983; 38: 257–63.
   PubMed Web of Science ®Google Scholar
• Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome – a double blind, placebo-controlled, randomized study. Clin Nutr. 2005; 24: 925–31. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Ligaarden SC, Axelsson L, Naterstad K, Lydersen S, Farup PG. A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial. BMC Gastroenterol. 2010; 10: 16. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ. A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol. 2011; 45: 679–83. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Kabir MA, Ishaque SM, Ali MS, Mahmuduzzaman M, Hasan M. Role of Saccharomyces boulardii in diarrhea predominant irritable bowel syndrome. Mymensingh Med J. 2011; 20: 397–401.
   PubMedGoogle Scholar
• Gade J, Thorn P. Paraghurt for patients with irritable bowel syndrome. A controlled clinical investigation from general practice. Scand J Prim Health Care. 1989; 7: 23–6. 10.3402/mehd.v23i0.18573.
   PubMedGoogle Scholar
• Kajander K, Hatakka K, Poussa T, Färkkilä M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther. 2005; 22: 387–94. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Kajander K, Myllyluoma E, Rajilić-Stojanović M, Kyrönpalo S, Rasmussen M, Järvenpää S, et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther. 2008; 27: 48–57. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003; 17: 895–904. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005; 17: 687–96. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Guandalini S, Magazzù G, Chiaro A, La Balestra V, Di Nardo G, Gopalan S, et al. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr. 2010; 51: 24–30. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Saggioro A. Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol. 2004; 38: S104–6. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Williams EA, Stimpson J, Wang D, Plummer S, Garaiova I, Barker ME, et al. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2009; 29: 97–103. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Hong KS, Kang HW, Im JP, Ji GE, Kim SG, Jung HC, et al. Effect of probiotics on symptoms in Korean adults with irritable bowel syndrome. Gut Liver. 2009; 3: 101–7. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol. 2008; 32: 147–52. 10.3402/mehd.v23i0.18573.
   PubMedGoogle Scholar
• Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010; 59: 325–32. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009; 104: 1033–49. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Parkes GC, Sanderson JD, Whelan K. Treating irritable bowel syndrome with probiotics: the evidence. Proc Nutr Soc. 2010; 69: 187–94. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol. 2008; 14: 2650–61. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol. 2009; 9: 15. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Malinen E, Rinttilä T, Kajander K, Mättö J, Kassinen A, Krogius L, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol. 2005; 100: 373–82. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007; 133: 24–33. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Rajilić-Stojanović M, Smidt H, de Vos WM. Diversity of the human gastrointestinal tract microbiota revisited. Environ Microbiol. 2007; 9: 2125–36. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Krogius-Kurikka L, Lyra A, Malinen E, Aarnikunnas J, Tuimala J, Paulin L, et al. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol. 2009; 9: 95. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Kajander K, Krogius-Kurikka L, Rinttilä T, Karjalainen H, Palva A, Korpela R. Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. Aliment Pharmacol Ther. 2007; 26: 463–73. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Lyra A, Krogius-Kurikka L, Nikkilä J, Malinen E, Kajander K, Kurikka K, et al. Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. BMC Gastroenterol. 2010; 10: 110. 10.3402/mehd.v23i0.18573.
   Web of Science ®Google Scholar
• Michail S, Kenche H. Gut microbiota is not modified by randomized, double-blind, placebo-controlled trial of VSL#3 in diarrhea-predominant irritable bowel syndrome. Probiotics Antimicrob Proteins. 2011; 3: 1–7. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology. 2003; 124: 1662–71. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Ait-Belgnaoui A, Han W, Lamine F, Eutamene H, Fioramonti J, Bueno L, et al. Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction. Gut. 2006; 55: 1090–4. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Verdú EF, Bercik P, Verma-Gandhu M, Huang XX, Blennerhassett P, Jackson W, et al. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut. 2006; 55: 182–90. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007; 13: 35–7. 10.3402/mehd.v23i0.18573.
   PubMed Web of Science ®Google Scholar
• Marteau P. Probiotics in functional intestinal disorders and IBS: proof of action and dissecting the multiple mechanisms. Gut. 2010; 59: 285–6. 10.3402/mehd.v23i0.18573.
   Google Scholar